KENALOG IN ORABASE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KENALOG IN ORABASE (KENALOG IN ORABASE).
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
| Metabolism | Hepatic metabolism primarily via CYP3A4; undergoes reduction, oxidation, and conjugation. |
| Excretion | Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%). |
| Half-life | Terminal half-life approximately 2-5 hours following mucosal application. |
| Protein binding | Approximately 70-90% bound to corticosteroid-binding globulin and albumin. |
| Volume of Distribution | Estimated Vd of 1.5-3.5 L/kg, reflecting extensive tissue distribution. |
| Bioavailability | Systemic bioavailability via oral mucosa is low but not precisely quantified; local delivery is the primary route. |
| Onset of Action | Onset within minutes to hours; clinical effect typically noted 30 minutes after application. |
| Duration of Action | Duration of therapeutic effect is 4-6 hours; mucous membrane adhesion may last 2-3 hours. |
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
| Dosage form | PASTE |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use only if clearly needed and use the smallest effective amount. |
| Geriatric use | Use the smallest effective amount for the shortest duration due to increased potential for systemic effects with age. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KENALOG IN ORABASE (KENALOG IN ORABASE).
| Breastfeeding | Triamcinolone acetonide is excreted into human breast milk in low amounts following systemic administration. The milk-to-plasma ratio is unknown for topical oral formulation, but due to low systemic absorption, concentrations are expected to be negligible. No adverse effects on the infant have been reported with topical corticosteroids. Caution is advised with prolonged or extensive use. |
| Teratogenic Risk | Triamcinolone acetonide (KENALOG IN ORABASE) is a corticosteroid. Systemic absorption from oral mucosal application is minimal but may occur. In first trimester, corticosteroid use is associated with a small increased risk of oral clefts (odds ratio ~1.3-3.4). Second and third trimester use may cause fetal adrenal suppression, intrauterine growth restriction, and preterm birth if significant systemic exposure occurs. Topical use with minimal absorption is generally considered low risk, but theoretical risks persist. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Systemic fungal infections","Hypersensitivity to triamcinolone or any component of the formulation","Viral or bacterial infections of the oral mucosa (e.g., herpes simplex)"]
| Precautions | ["Immunosuppression may increase susceptibility to infections","Adrenal suppression with prolonged use","Avoid use in patients with known hypersensitivity to corticosteroids","Use with caution in patients with diabetes, hypertension, or osteoporosis","Do not swallow or apply to large areas of skin"] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal blood pressure, blood glucose, and signs of systemic corticosteroid effects. Fetal growth should be assessed via ultrasound if prolonged use occurs. Neonatal monitoring for adrenal suppression (hypoglycemia, poor feeding) if maternal exposure was extensive near term. |
| Fertility Effects | No direct studies on fertility effects of topical oral corticosteroids. Systemic high-dose corticosteroids may cause menstrual irregularities and reversible ovulatory dysfunction, but at typical doses of KENALOG IN ORABASE, systemic effects are minimal. No adverse effects on male fertility reported. |